Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABL DiagnosticsFRA:9BK0 54 3-Year ROIIC % is 491.49 as of Dec. 2025, which is 10774% above its 10-year median of 4.52. GuruFocus rates FRA:9BK0 with a GF Score™ of 54/100 and a GF Value™ of €7.48 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 619 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 97.74% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
ABL Diagnostics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 491.49%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for ABL Diagnostics's 3-Year ROIIC % or its related term are showing as below:
FRA:9BK0's 3-Year ROIIC % is ranked better than 97.74% of 619
companies
in the Healthcare Providers & Services industry
Industry Median: 3.48
vs FRA:9BK0: 491.49
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ABL Diagnostics 3-Year ROIIC % Related Terms
ABL Diagnostics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9BK0 vs VEEV, BTSG, HQY: 3-Year ROIIC % Comparison
For the Health Information Services subindustry, ABL Diagnostics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's 3-Year ROIIC % falls into.
ABL Diagnostics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 0.29 (Dec. 2025) - 0.059 (Dec. 2022) )
/
( 9.085 (Dec. 2025) - 9.038 (Dec. 2022) )
=
0.231
/
0.047000000000001
=
491.49%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
ABL Diagnostics (FRA:9BK0) has a 3-Year ROIIC % of 491.49 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ABL Diagnostics and its competitors. This is 10774% above median its historical median of 4.52. Over the past decade, ABL Diagnostics' 3-Year ROIIC % has ranged from 1.45 to 491.49. According to the industry distribution chart, ABL Diagnostics ranks #14 out of 619 companies in the Healthcare Providers & Services industry, placing it in the top 2.3%.
Is ABL Diagnostics' 3-Year ROIIC % too high?
ABL Diagnostics' current 3-Year ROIIC % of 491.49 is 10774% above median its 10-year median of 4.52. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 491.49. The Healthcare Providers & Services industry median 3-Year ROIIC % is 3.48. ABL Diagnostics' value of 491.49 is 14023.3% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #14 out of 619 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, ABL Diagnostics has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' 3-Year ROIIC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #14 out of 619 companies for 3-Year ROIIC %. This places ABL Diagnostics in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.48. ABL Diagnostics' value of 491.49 is 14023.3% above this benchmark. Historically, ABL Diagnostics' own 3-Year ROIIC % has ranged from 1.45 to 491.49 over the past decade. While the company's 10-year median is 4.52 vs. the industry median of 3.48, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.48, based on 619 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current 3-Year ROIIC % of 491.49 is 14023.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current 3-Year ROIIC % is 491.49, which is 10774% above median its own 10-year median of 4.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (FRA:9BK0) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.48, compared to a current price of €2.76 — trading 63.1% below its estimated fair value. The current 3-Year ROIIC % is 491.49, which is 10774% above median its 10-year median of 4.52 and 14023.3% above the Healthcare Providers & Services industry median of 3.48. ABL Diagnostics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For ABL Diagnostics (FRA:9BK0), the current 3-Year ROIIC % is 491.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (FRA:9BK0) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.76 is trading 63.1% below its estimated GF Value™ of €7.48.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for FRA:9BK0:
3-Year ROIIC %: 491.49 (10774% above median its 10-year median of 4.52)
GF Value™: €7.48 vs. price of €2.76 (63.1% below fair value)
Industry Position: 14023.3% above the Healthcare Providers & Services median (#14 of 619)
No single metric tells the full story. See the FRA:9BK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
54GF Score
Get the complete analysis for FRA:9BK0
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9BK0 has been successfully added to your 
